10x Genomics (TXG) Stock Forecast, Price & News

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for 10x Genomics in the last year. There are currently 1 sell rating, 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" TXG shares.
View TXG analyst ratings or view top-rated stocks.

9 Wall Street research analysts have issued 1-year price objectives for 10x Genomics' shares. Their TXG share price forecasts range from $25.00 to $75.00. On average, they expect the company's stock price to reach $57.00 in the next year. This suggests a possible upside of 38.2% from the stock's current price.
View analysts price targets for TXG or view top-rated stocks among Wall Street analysts.

10x Genomics' stock was trading at $36.44 at the start of the year. Since then, TXG stock has increased by 13.2% and is now trading at $41.25.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our TXG earnings forecast.

10x Genomics, Inc. (NASDAQ:TXG) issued its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.53) earnings per share for the quarter, missing analysts' consensus estimates of ($0.39) by $0.14. The company earned $146.82 million during the quarter, compared to analysts' expectations of $139.97 million. 10x Genomics had a negative trailing twelve-month return on equity of 21.69% and a negative net margin of 30.31%. The company's revenue for the quarter was up 28.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.57) EPS.

ETFs with the largest weight of 10x Genomics (NASDAQ:TXG) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), ARK Genomic Revolution ETF (ARKG), Fidelity Disruptive Medicine ETF (FMED), ARK Innovation ETF (ARKK), BNY Mellon Innovators ETF (BKIV), Invesco Dorsey Wright Healthcare Momentum ETF (PTH) and Principal Healthcare Innovators ETF (BTEC).

10x Genomics updated its FY 2023 earnings guidance on Thursday, August, 3rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $600.00 million-$620.00 million, compared to the consensus revenue estimate of $600.73 million.

25 employees have rated 10x Genomics Chief Executive Officer Serge Saxonov on Glassdoor.com. Serge Saxonov has an approval rating of 100% among the company's employees. This puts Serge Saxonov in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

(TXG) raised $297 million in an IPO on Thursday, September 12th 2019. The company issued 9,000,000 shares at a price of $31.00-$35.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen was co-manager.

10x Genomics trades on the NASDAQ under the ticker symbol "TXG."

Shares of TXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TXG stock can currently be purchased for approximately $41.25.

10x Genomics (NASDAQ:TXG) has a market capitalization of $4.84 billion and generates $516.41 million in revenue each year. The company earns $-166,000,000.00 in net income (profit) each year or ($1.49) on an earnings per share basis.

The company employs 1,243 workers across the globe.

10x Genomics' mailing address is 6230 STONERIDGE MALL ROAD, PLEASANTON CA, 94588. The official website for the company is www.10xgenomics.com. The company can be reached via phone at 925-401-7300 or via email at investors@10xgenomics.com.